Katharina Bell

ORCID: 0000-0003-4127-1635
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glaucoma and retinal disorders
  • Retinal Diseases and Treatments
  • Retinal Development and Disorders
  • Corneal surgery and disorders
  • Neurological Disorders and Treatments
  • Ocular Surface and Contact Lens
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Nicotinic Acetylcholine Receptors Study
  • Parkinson's Disease Mechanisms and Treatments
  • Autophagy in Disease and Therapy
  • Cell Adhesion Molecules Research
  • Connexins and lens biology
  • Retinal and Optic Conditions
  • Retinal Imaging and Analysis
  • S100 Proteins and Annexins
  • Ocular Infections and Treatments
  • Ophthalmology and Eye Disorders
  • 14-3-3 protein interactions
  • Endoplasmic Reticulum Stress and Disease
  • Immune Response and Inflammation
  • Migraine and Headache Studies
  • Retinopathy of Prematurity Studies
  • Nuclear Receptors and Signaling
  • melanin and skin pigmentation
  • Cardiovascular Syncope and Autonomic Disorders

National Health and Medical Research Council
2023-2025

Cooperative Trials Group for Neuro-Oncology
2025

The University of Sydney
2023-2025

Duke-NUS Medical School
2021-2025

Vision Cooperative Research Centre
2025

Singapore Eye Research Institute
2021-2024

Singapore National Eye Center
2021-2023

University Medical Center of the Johannes Gutenberg University Mainz
2012-2022

Johannes Gutenberg University Mainz
2013-2022

Centro de Investigaciones Biológicas Margarita Salas
2020

Purpose To evaluate the safety and tolerability of intravitreal ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy (TE; filtration surgery). Methods In this prospective phase I trial scheduled for TE mitomycin C (MMC) received a single injection ISTH0036 at end surgery escalating total doses 6.75 μg, 22.5 67.5 μg or 225 resulting calculated intraocular...

10.1371/journal.pone.0188899 article EN cc-by PLoS ONE 2017-11-30
Jason Bacharach Andrew J. Tatham Gloria E. Ferguson Sandra Belalcázar Hagen Thieme and 95 more Margot L. Goodkin Michelle Y. Chen Qiang Guo Jeen Liu Michael R. Robinson Marina Bejanian David Wirta Arturo Alezzandrini Gabriel Bercovich Pablo Deromedis Federico Furno Sola Carolina Gentile S. Lerner Anahi Lupinacci Carlos Zeolite Catherine M. Birt Andrew Crichton Sébastien Gagné Michael Giunta Paul Harasymowycz Delan Jinapriya Marcelo T. Nicolela Donald R. Nixon Patrick Saurel David Yan Darana Yuen Santiago Arango Sandra Belalcázar Alexander Martínez Juan Camilo Restrepo Vladimír Korda Jana Kadlecová Jitka Svačinová Hany A. Khairy Hani El Ibiary Zeinab El Sanabary Katharina Bell Roman Greslechner Joerg Michael Koch K Lorenz Isabel Oberacher-Velten Stefanie Schmickler C Schuart Hagen Thieme Francesco Bandello Carlo Cagini Michele Figus Leonardo Mastropasqua Luca Rossetti Maurizio G. Uva Sandragasu Thayanithi Anthony P. Wells Rahat Husain Victor Koh Dawn Lim Tin Aung Petrus Gous Lynette Venter Changwon Kee Michael S. Kook Ki Ho Park Muhsin Eraslan Özcan Kayıkçıoğlu Nilgün Yıldırım Rupert Bourne Anshoo Choudhary M. Francesca Cordeiro Vincent Dubois James Kirwan Sheng Yang Lim Keith R. Martin Antony Nithy Avinash Prabhu Andrew J. Tatham Ahmad Amir Jason Bacharach Howard Barnebey Allen D. Beck Lance Bergstrom Navaneet S.C. Borisuth James D. Branch Jonathan Briggs Stephen Bylsma Peter Chang William C. Christie Frank Cotter Michael Depenbusch Damien F. Goldberg Jack V. Greiner Shailesh Gupta Ron Gutmark Ying Han Sebastian Heersink Malik Y. Kahook Albert S Khouri

To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 OAG OHT an open iridocorneal angle inferiorly study eye. Study eyes were administered on day 1, week 16, 32, twice-daily topical timolol maleate 0.5%. Primary endpoints IOP change from baseline through 12. Safety measures...

10.1007/s40265-021-01624-9 article EN cc-by-nc Drugs 2021-11-01

ABSTRACT Age and elevated intraocular pressure (IOP) are the two major risk factors for developing glaucoma, a leading cause of blindness worldwide that is characterized by loss retinal ganglion cells (RGCs). Although vision irreversible over long term, accumulating evidence points to short‐term improvement in glaucoma patients response certain interventions, suggesting RGCs have capacity recover function. In present study, we sought investigate mechanisms underlying recovery RGC function...

10.1111/acel.70005 article EN cc-by Aging Cell 2025-02-27

Glaucoma is a common age-related disease leading to progressive retinal ganglion cell (RGC) death, visual field defects and vision loss the second cause of blindness in elderly worldwide. Mitochondrial dysfunction impaired autophagy have been linked glaucoma induction shows neuroprotective effects animal models. We shown that decreases with aging retina can be for RGCs, but it currently unknown how deficiency impact RGCs susceptibility survival. Using optic nerve crush model young...

10.1038/s41420-020-0257-4 article EN cc-by Cell Death Discovery 2020-04-17

Mitochondrial damage plays a prominent role in glaucoma. The only way cells can degrade whole mitochondria is via autophagy, process called mitophagy. Thus, studying mitophagy the context of glaucoma essential to understand disease. Up date limited tools are available for analyzing vivo. We have taken advantage mito-QC reporter, recently generated mouse model that allows an accurate assessment fill this gap. used primary RGCs and retinal explants derived from mice quantify activation vitro...

10.3390/ijms21051882 article EN International Journal of Molecular Sciences 2020-03-10

Purpose: The aim of this study was to explore the roles crystallins in context aging glaucoma and potential mechanisms neuroprotection an experimental animal model glaucoma. Methods: Intraocular pressure (IOP) significantly elevated for 8 weeks animals at different ages (10 days, 12 weeks, 44 weeks) by episcleral vein cauterization. Retinal ganglion cells (RGCs) were quantified anti-Brn3a immunohistochemical staining (IHC). Proteomics using ESI-LTQ Orbitrap XL-MS used analyze presence...

10.1167/iovs.63.8.3 article EN cc-by-nc-nd Investigative Ophthalmology & Visual Science 2022-07-11

Glaucoma, a neurodegenerative disease, is characterized by progressive loss of retinal ganglion cells (rgc). Up- and down-regulated autoantibody immunoreactivities in glaucoma patients have been demonstrated. Previous studies showed protective effects antibodies [gamma (γ)-synuclein glial fibrillary acidic protein [GFAP]) on neuroretinal cells. The aim this study was to test these antibody rgc an organ culture model get better understanding cell-cell interactions the retina context effect....

10.1111/jnc.13765 article EN Journal of Neurochemistry 2016-08-10

Purpose Previous studies show significantly specifically changed autoantibody reactions against retinal antigens in the serum of glaucoma and ocular hypertension (OHT) patients comparison to healthy people. As pathogenesis still is unknown aim this study was analyze if antibodies interact with neuroretinal cells. Methods R28 cells were incubated suffering from primary open angle (POAG), normal tension (NTG) or OHT, POAG after antibody removal people for 48 h under a an elevated pressure...

10.1371/journal.pone.0046910 article EN cc-by PLoS ONE 2012-10-11

Previous studies demonstrate changes of autoantibody concentrations against retinal and optic nerve head antigens in the serum glaucoma patients comparison to healthy persons. These antibodies belong natural autoimmunity. showed up regulated, but also significantly down-regulated levels. have ability influence protein profiles neuroretinal cells possibly hold neuroprotective potential, as we been able before. Aim this study was analyse antibody effect on more detail determine impact found...

10.1186/s12886-015-0044-9 article EN cc-by BMC Ophthalmology 2015-06-26

Autoantibody profiling has gained increasing interest in the research field of glaucoma promising detection highly specific and sensitive marker candidates for future diagnostic purposes. Recent studies demonstrated that immune responses are characterized by expression congruent or similar complementarity determining regions (CDR) different individuals could be used as molecular targets biomarker discovery. Main objective this study was to characterize glaucoma-specific peptides from...

10.1093/hmg/ddx332 article EN Human Molecular Genetics 2017-09-19

The pathogenesis of glaucoma, a common neurodegenerative disease, involves an immunologic component. Changes in the natural autoantibody profile glaucoma patients were detected, showing not only up-regulated but also down-regulated immunoreactivities. In recent studies we able to demonstrate that antibody changes have large influence on protein profiles neuroretinal cells. Furthermore could neuroprotective potential one antibodies (γ-synuclein antibody). Anti-GFAP is another found patients....

10.1016/j.jphs.2014.12.019 article EN cc-by-nc-nd Journal of Pharmacological Sciences 2015-02-18

The family of synuclein proteins (α, β and γ) are related to neurodegenerative disease e.g. Parkinson Morbus Alzheimer. Additionally, a connection between γ-synuclein glaucoma, characterized by progressive loss retinal ganglion cells, which finally leads blindness, exists. reason for the development glaucoma is still unknown. Recent studies evaluating participation immunological components, demonstrate complex changed antibody reactivities in patients comparison healthy people, showing not...

10.1371/journal.pone.0090737 article EN cc-by PLoS ONE 2014-03-03
Justus G. Garweg Jana Štefaničková Carel C B Hoyng Thomas Schmelter Tobias Niesen and 88 more Olaf Sowade Sobha Sivaprasad Alfredo Adán Mikulas Alexik Fareed Ali Miguel Amaro Vilma Jūratė Balčiūnienė Francesco Bandello L. Arias Barquet Anna Beck Katharina Bell Francesco Boscia Anniken Burés Ângela Carneiro David R. Chow Andrius Cimbalas Claudia Dahlke Deepali Varma John D. Dickinson Michael Dollin Chiara M. Eandi Karl-Heinz Emmerich Nicolas Feltgen João Figueira Oliver Findl Monika Gajdošová Richard Gale Ivan Galić Justus G. Garweg Vanessa Gasser‐Steiner Michel Giunta John R. Gonder Andrzej Grzybowski Jan Hamouz Lars‐Olof Hattenbach Frank G. Holz Jesia Hasan J Kałuźny Ágnes Kerényi Peter J. Kertes Frank Koch Laurent Kodjikan David E. Lederer I Liehneová Katrin Lorenz Andrew Lotery Martin McKibbin Geeta Menon Zofia Michalewska Edoardo Midena Massimo Nicolò András Papp Gabriela Pavlovičová Enrico Peiretti Sara Vaz-Pereira Paolo Perri Ioannis N. Petropoulos Frederic Queguiner Krystyna Raczyńska Laura Sararols-Ramsay Marek Rękas Federico Ricci Bożena Romanowska‐Dixon Helmut Sachs Saddek Mohand‐Saïd Dirk Sandner Ursula Schmidt‐Erfurth Walter Sekundo András Seres Sobha Sivaprasad Eric H. Souied João Paulo Castro Sousa Andrzej Stankiewicz Jana Štefaničková K. Struharova Jan Studnička Enrique Cervera Taulet Simon Taylor Sławomir Teper Attila Vajas Carlos Cava Valenciano Balázs Varsányi Francesco Viola Gianni Virgili Lars Wagenfeld Gavin Walters Peter Wiedemann Tomasz Żarnowski

To examine vision-related quality of life in patients with diabetic macular edema (DME) treated intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Inc, Tarrytown, NY). AQUA was a multicenter, open-label, single-arm, phase 4 study. Adults 18 years age or older type 1 2 diabetes mellitus and DME. Patients received mg every 8 weeks for 52 weeks, after 5 initial doses weeks. The primary outcome the change 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) total...

10.1016/j.oret.2019.03.012 article EN cc-by-nc-nd Ophthalmology Retina 2019-03-21

Many studies analyzing neurodegenerative diseases demonstrate altered frequencies of regulatory T cells (Tregs). Till date, there is hardly any information concerning Tregs in glaucoma. To gather first results Treg levels glaucoma patients, we aimed to investigate whether the number CD4(+)CD25(+)T vary patients suffering from primary open-angle (POAG) and healthy controls.Heparinized blood samples were collected 16 individuals POAG patients. The groups age gender matched. A density gradient...

10.1080/02713683.2016.1205629 article EN Current Eye Research 2016-10-10
Coming Soon ...